Lexaria Bioscience Corp. (LEXXW) Financial Statements (2025 and earlier)
Company Profile
| Business Address |
100 - 740 MCCURDY ROAD KELOWNA, BC V1X 2P7 |
| State of Incorp. | NV |
| Fiscal Year End | August 31 |
| Industry (SIC) | 2834 - Pharmaceutical Preparations (benchmarking) |
| More info | Complete Financial Analysis Financial Benchmarking |
Balance Sheet (Statement of Financial Position) ($ in thousands)
| 2/28/2025 MRQ | 11/30/2024 MRQ | 8/31/2024 | 8/31/2023 | 8/31/2022 | 8/31/2021 | 8/31/2020 | |||
|---|---|---|---|---|---|---|---|---|---|
| ASSETS | |||||||||
| Current Assets | |||||||||
| Cash, cash equivalents, and short-term investments | 40 | 56 | 126 | 6,161 | 11,752 | 1,313 | |||
| Cash and cash equivalent | 5,813 | 10,918 | 1,294 | ||||||
| Short-term investments | 40 | 56 | 126 | 347 | 834 | 19 | |||
| Receivables | 263 | 154 | 175 | 202 | 342 | 314 | |||
| Inventory, net of allowances, customer advances and progress billings | 38 | 30 | 117 | ||||||
| Inventory | 38 | 30 | 117 | ||||||
| Prepaid expense | 547 | 577 | 319 | 182 | |||||
| Other undisclosed current assets | 8,522 | 7,688 | 1,352 | ||||||
| Total current assets: | 8,826 | 7,898 | 2,200 | 6,978 | 12,443 | 1,926 | |||
| Noncurrent Assets | |||||||||
| Finance lease, right-of-use asset, after accumulated amortization | 128 | 135 | 167 | 52 | |||||
| Operating lease, right-of-use asset | 127 | ||||||||
| Property, plant and equipment | 271 | 255 | 254 | 316 | 368 | 483 | |||
| Long-term investments and receivables, including: | 64 | 64 | |||||||
| Long-term investments | 14 | ||||||||
| Other undisclosed long-term investments and receivables | 64 | 50 | |||||||
| Intangible assets, net (including goodwill) | 505 | 517 | 463 | 292 | |||||
| Intangible assets, net (excluding goodwill) | 505 | 517 | 463 | 292 | |||||
| Other undisclosed noncurrent assets | 488 | 456 | |||||||
| Total noncurrent assets: | 968 | 970 | 884 | 856 | 824 | 902 | |||
| TOTAL ASSETS: | 9,794 | 8,868 | 3,084 | 7,834 | 13,267 | 2,828 | |||
| LIABILITIES AND EQUITY | |||||||||
| Liabilities | |||||||||
| Current Liabilities | |||||||||
| Accounts payable and accrued liabilities, including: | 269 | 1,066 | 240 | 151 | 101 | 87 | |||
| Other undisclosed accounts payable and accrued liabilities | 269 | 1,066 | 240 | 151 | 101 | 87 | |||
| Debt | 28 | 28 | 43 | 8 | |||||
| Due to related parties | ✕ | ✕ | ✕ | ✕ | 5 | 59 | |||
| Other undisclosed current liabilities | 29 | 5 | 39 | 80 | |||||
| Total current liabilities: | 298 | 1,099 | 268 | 194 | 153 | 226 | |||
| Noncurrent Liabilities | |||||||||
| Long-term debt and lease obligation | 109 | 136 | 7 | 50 | 89 | ||||
| Finance lease, liability | 109 | 136 | 7 | ||||||
| Liabilities, other than long-term debt | 102 | ||||||||
| Operating lease, liability | 102 | 50 | 89 | ||||||
| Other undisclosed noncurrent liabilities | (50) | (59) | |||||||
| Total noncurrent liabilities: | 102 | 109 | 136 | 7 | 50 | 120 | |||
| Total liabilities: | 400 | 1,209 | 404 | 201 | 203 | 346 | |||
| Equity | |||||||||
| Equity, attributable to parent, including: | 9,774 | 8,036 | 3,044 | 7,949 | 13,064 | 2,525 | |||
| Common stock | 17 | 16 | 8 | 6 | 6 | 90 | |||
| Additional paid in capital | 64,042 | 59,599 | 48,799 | 47,041 | 45,089 | 30,237 | |||
| Accumulated other comprehensive loss | (23) | (20) | |||||||
| Accumulated deficit | (54,262) | (51,559) | (45,763) | (39,099) | (31,829) | (27,802) | |||
| Other undisclosed equity, attributable to parent | (202) | ||||||||
| Equity, attributable to noncontrolling interest | (380) | (377) | (364) | (316) | (43) | ||||
| Total equity: | 9,394 | 7,659 | 2,680 | 7,632 | 13,064 | 2,482 | |||
| TOTAL LIABILITIES AND EQUITY: | 9,794 | 8,868 | 3,084 | 7,834 | 13,267 | 2,828 | |||
Income Statement (P&L) ($ in thousands)
| 2/28/2025 TTM | 11/30/2024 TTM | 8/31/2024 | 8/31/2023 | 8/31/2022 | 8/31/2021 | 8/31/2020 | ||
|---|---|---|---|---|---|---|---|---|
| Revenues | 497 | 464 | 226 | 255 | 723 | 385 | ||
| Cost of revenue (Cost of Product and Service Sold) | (3) | (5) | (32) | (72) | (175) | (99) | ||
| Gross profit: | 494 | 459 | 195 | 184 | 547 | 285 | ||
| Operating expenses | (7,799) | (6,213) | (6,729) | (7,567) | (6,234) | (4,370) | ||
| Operating loss: | (7,305) | (5,753) | (6,534) | (7,384) | (5,687) | (4,085) | ||
| Nonoperating expense | (26) | (56) | (179) | (22) | ||||
| Investment income, nonoperating | (22) | |||||||
| Other nonoperating expense | (26) | (56) | (179) | |||||
| Interest and debt expense | (8) | |||||||
| Other undisclosed income (loss) from continuing operations before equity method investments, income taxes | (8) | 1,539 | 98 | |||||
| Loss from continuing operations before equity method investments, income taxes: | (7,338) | (5,816) | (6,713) | (7,384) | (4,170) | (3,987) | ||
| Other undisclosed income from continuing operations before income taxes | 8 | 8 | ||||||
| Loss from continuing operations before income taxes: | (7,330) | (5,809) | (6,713) | (7,384) | (4,170) | (3,987) | ||
| Income tax expense | (2) | |||||||
| Loss from continuing operations: | (7,330) | (5,809) | (6,713) | (7,384) | (4,170) | (3,989) | ||
| Loss before gain (loss) on sale of properties: | ✕ | ✕ | ✕ | ✕ | (7,384) | (4,192) | (3,989) | |
| Loss from discontinued operations | (22) | |||||||
| Other undisclosed net income | 14,767 | |||||||
| Net income (loss): | (7,330) | (5,809) | (6,713) | 7,384 | (4,192) | (3,989) | ||
| Net income attributable to noncontrolling interest | 11 | 13 | 48 | 114 | 159 | 151 | ||
| Other undisclosed net loss attributable to parent | (14,767) | (153) | (246) | |||||
| Net loss attributable to parent: | (7,320) | (5,795) | (6,665) | (7,269) | (4,186) | (4,085) | ||
| Other undisclosed net income available to common stockholders, basic | 159 | 151 | ||||||
| Net loss available to common stockholders, diluted: | (7,320) | (5,795) | (6,665) | (7,269) | (4,027) | (3,934) | ||
Comprehensive Income ($ in thousands)
| 2/28/2025 TTM | 11/30/2024 TTM | 8/31/2024 | 8/31/2023 | 8/31/2022 | 8/31/2021 | 8/31/2020 | ||
|---|---|---|---|---|---|---|---|---|
| Net income (loss): | (7,330) | (5,809) | (6,713) | 7,384 | (4,192) | (3,989) | ||
| Other comprehensive loss | (7,384) | |||||||
| Comprehensive loss: | (7,330) | (5,809) | (6,713) | (4,192) | (3,989) | |||
| Comprehensive income, net of tax, attributable to noncontrolling interest | 11 | 13 | 48 | 114 | 159 | |||
| Other undisclosed comprehensive loss, net of tax, attributable to parent | (27) | (20) | ||||||
| Comprehensive loss, net of tax, attributable to parent: | (7,347) | (5,815) | (6,665) | (7,269) | (4,033) | (3,989) | ||
Statements Sources
The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.